Heron Therapeutics (NASDAQ:HRTX) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Heron Therapeutics (NASDAQ:HRTX) announced its earnings results on Monday. The biotechnology company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.01), FiscalAI reports. Heron Therapeutics had a negative net margin of 22.52% and a negative return on equity of 293.02%. The firm had revenue of $35.25 million during the quarter, compared to analysts’ expectations of $37.50 million.

Heron Therapeutics Price Performance

Shares of NASDAQ:HRTX opened at $0.29 on Monday. The company has a market capitalization of $55.63 million, a P/E ratio of -1.54 and a beta of 1.65. The company’s 50-day moving average is $0.32 and its 200 day moving average is $0.67. The company has a debt-to-equity ratio of 24.35, a quick ratio of 1.51 and a current ratio of 2.49. Heron Therapeutics has a fifty-two week low of $0.26 and a fifty-two week high of $1.57.

Analyst Ratings Changes

Several research firms recently weighed in on HRTX. Zacks Research upgraded shares of Heron Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, August 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Heron Therapeutics in a research note on Thursday, October 15th. HC Wainwright cut shares of Heron Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 11th. Finally, Wall Street Zen upgraded Heron Therapeutics to a “sell” rating in a research note on Saturday, August 8th. Three equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Reduce” and an average price target of $2.00.

About Heron Therapeutics

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and marketing medicines for acute care and oncology supportive care. Its products are designed to address unmet needs such as postoperative pain and chemotherapy-induced nausea and vomiting.

The company’s portfolio includes ZYNRELEF, an extended-release solution combining bupivacaine and meloxicam for the management of postoperative pain in adults. Heron also markets CINVANTI, an injectable formulation of aprepitant used as part of a combination regimen to help prevent acute and delayed nausea and vomiting associated with highly or moderately emetogenic cancer chemotherapy.

Heron’s commercial activities are primarily focused on the United States, where it works with healthcare providers and institutions to support the use of its products in surgical and oncology settings.